Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARα agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6773-6778

  Matthews, Jay M ^a   Chen, Xiaoli ^a   Cryan, Ellen ^a   Hlasta, Dennis J ^a   Rybczynski, Philip J ^a   Strauss, Kim ^a   Tang, Yuting ^a   Xu, June Z ^a   Yang, Maria ^a   Zhou, Lubing ^a   Demarest, Keith T ^a  

^a Drug Discovery   (United States)

Author keywords

Aminoindane; Dyslipidemia; Hypoglycemic; Hypolipidemic; PPAR agonist

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3 ENOYLHYDROXYACYL COENZYME A DEHYDROGENASE; GLUCOSE; INDAN DERIVATIVE; INDANUREIDOTHIOISOBUTYRIC ACID; ISOBUTYRIC ACID DERIVATIVE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CIRCULAR DICHROISM; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; FEMALE; GENE INDUCTION; GLUCOSE BLOOD LEVEL; HEPATOMA CELL; HUMAN; HUMAN CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RACEMIC MIXTURE; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AMINO ACIDS; ANIMALS; BUTYRIC ACIDS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HUMANS; INDANS; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

MUS; RATTUS;

EID: 35848929251     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.041     Document Type: Article

References (24)

1. Berger J., and Moller D.E. Annu. Rev. Med. 53 (2002) 409
2. Berger J.P., Akiyama T.E., and Meinke P.T. Trends Pharmcol. Sci. 26 (2005) 244
3. Chinetti-Gbaguidi G., Fruchart J.-C., and Staels B. Curr. Opin. Pharmacol. 5 (2005) 177
4. Henke B.R. J. Med. Chem. 47 (2004) 4118
5. Issemann I., and Green S. Nature 347 (1990) 645
6. Ram V.J. Drugs Today 39 (2003) 609
7. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Nature 358 (1992) 771
8. Desai R.C., Metzger E., Santini C., Meinke P.T., Heck J.V., Berger J.P., MacNaul K.L., Cai T.-Q., Wright S.D., Agrawal A., Moller D.E., and Sahoo S.P. Bioorg. Med. Chem. Lett. 16 (2006) 1673
9. Shi G.Q., Dropinski J.F., Zhang Y., Santini C., Sahoo S.P., Berger J.P., MacNaul K.L., Zhou G., Agrawal A., Alvaro R., Cai T.-Q., Hernandez M., Wright S.D., Moller D.E., Heck J.V., and Meinke P.T.T. J. Med. Chem. 48 (2005) 5589
10. Nomura M., Tanase T., Ide T., Tsunoda M., Suzuki M., Uchiki H., Murakami K., and Miyachi H. J. Med. Chem. 46 17 (2003) 3581
11. Miyachi H., Nomura M., Tanase T., Takahashi Y., Ide T., Tsunoda M., Murakami K., and Awano K. Bioorg. Med. Chem. Lett. 12 (2001) 77
12. Koyama H., Boueres J.K., Miller D.A., Berger J.P., MacNaul K.L., Wang P., Ippolito M.C., Wright d.D., Agrawal A.K., Moller D.A., and Sahoo S.P. Bioorg. Med. Chem. Lett. 15 (2005) 3347
13. Xu Y., Mayhugh D., Saeed A., Wang X., Thompson R.C., Dominianni S.J., Kauffman R.F., Singh J., Bean J.S., Bensch W.R., Barr R.W., Osborne J., Montrose-Rafizadeh C., Zink R.W., Yumibe N.P., Huang N., Luffer-Atlas D., Rungta D., Maise D.E., and Mantlo N.B. J. Med. Chem. 46 (2003) 5121
14. Li Z., Liao C., Ko B., Shan S., Tong E., Yin Z., Pan D., Wong V., Shi L., Ning Z.-Q., Hu W., Zhou J., Chung S., and Lu Z.-P. Bioorg. Med. Chem. Lett. 14 (2004) 3507
15. Sauerberg P., Bury P.S., Mogensen J.P., Deussen H.-J., Pettersson I., Fleckner J., Nehlin J., Frederiksen K.S., Albrektsen T., Din N., Svensson A., Ynddal L., Wulff E.M., and Jeppesen L. J. Med. Chem. 46 (2003) 4883
16. Brown P.J., Smith-Oliver T.A., Charifson P.S., Tomkinson N., Fivush A.M., Sternbach D.D., Wade L.E., Orband-Miller L., Parks D.J., Blanchard S.G., Kliewer S.A., Lehmann J.M., and Willson T.M. Chem. Biol. 4 (1997) 909
17. Bown P.J., Winegar D.A., Plunket K.D., Moore L.S., Wu Z., Chapman J.M., Kliewer S.A., and Wilson T.M. J. Med. Chem. 42 (1999) 3788
18. Brown P.J., Stuart L.W., Hurley K.P., Lewis M.C., Winegar D.A., and Wilson J.G. Bioorg. Med. Chem. Lett. 11 9 (2001) 1225
19. BioTools, 17546 Bee Line Hwy, Jupiter, FL 33458. X-ray crystallography of an advanced intermediate of R-(-)-35 was obtained to verify the absolute configuration and will be published in a separate manuscript.
20. -5 M).
21. Compounds were tested by Absorption Systems, in Exton, PA.
22. 2 (70:30) and bled by retro-orbital sinus puncture into microtubes containing c log activator and put on ice. The serum samples were prepared by centrifugation). Serum glucose and triglycerides were determined using COBAS Mira Plus blood chemistry analyzer (Roche Diagnostics, NJ). Serum insulin was measured using ALPCO insulin ELISA kit.
23. 2 incubator overnight. The cells were challenged with test compounds, incubated for 24 h at 37 °C. The luciferase activity was assayed using the Steady-Glo Luciferase Assay Kit from Promega.
24. Burris T.P., Pelton P.D., and Zhou L. Mol. Endocinol. 13 (1999) 410 (aP2 assay)